Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares

BVF Partners L.P. sold 3,750,000 shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) on April 2, 2026 for about $62.96M, a sale the filing states represented 78.30% of BVF's direct holdings. The filing reports post-transaction direct holdings of ~15.94M shares (post-sale value ~$267.66M) and the article notes the sale trimmed roughly 19% of BVF’s prior position; MoonLake closed at $16.79 (market cap ~$1.25B, 1‑yr change -53.35%). The transaction appears to be portfolio rebalancing rather than a full exit and is likely to have limited impact beyond near-term pressure on MLTX (market-impact ~0.35).

Analysis

A large, visible trim by a prominent biotech investor is more signal of portfolio-level positioning than a binary judgment on the molecule. Expect a short-lived liquidity overhang: systematic funds and volatility-targeting algos can amplify any intraday weakness, creating a 1–4 week window where price dislocations exceed fundamentals.

Operationally, MoonLake’s risk-reward remains driven by clinical milestones; binary readouts over the next 3–12 months will dominate returns and can easily overwhelm incremental supply from a single holder. The plausible paths are asymmetric — a positive confirmation could re-rate the stock by multiples as comparable specialty immunology acquisitions and premium pricing for differentiated modalities remain prevalent, while negative outcomes compress value toward cash and near-term burn.

From a positioning perspective, the move creates a tactical entry opportunity for structured exposure: keep directional exposure time-horizon aligned to the clinical calendar and cap headline risk with defined-loss option structures. Monitor filings and block trade prints over the next 2–6 weeks for signs of follow-on selling; if follow-through is absent, mean-reversion to pre-trim levels is likely within 1–3 months absent new clinical data.

Key Decisions for Investors

• Long-dated call spread (MLTX): Buy Jan-2028 $25 call / sell Jan-2028 $40 call — entry now or on a 10–15% price pullback. Rationale: asymmetric upside if trials remain on track; capped cost limits downside to premium paid (target 2–4x return if positive readouts within 12–24 months).
• Event-timed directional (MLTX): Build a limited-size long position on a 10–15% dip, size to 1–2% of portfolio, set a hard stop of 12% below entry and tiered profit targets at +50% and +100% over 6–12 months. Rationale: captures mean-reversion while preserving capital if sentiment deteriorates.
• Hedge-funded calendar (MLTX): Buy 12–18 month ATM calls and sell 3–6 month ATM calls to fund premium. Use this if implied vol spikes post-sale; trade aims for positive carry into longer-dated catalysts with finite downside (theta-funded).